Expression of the inhibitor of apoptosis protein family in multiple sclerosis reveals a potential immunomodulatory role during autoimmune mediated demyelination

Multiple Sclerosis

Volumn 14, Issue 5, 2008, Pages 577-594

  Hebb, A L O ^a   Moore, C S ^a   Bhan, V ^b   Campbell, T ^b   Fisk, J D ^b,c   Robertson, H A ^a   Thorne, M ^a   Lacasse, E ^d   Holcik, M ^e   Gillard, J ^d   Crocker, S J ^f   Robertson, G S ^a,b  

^a DALHOUSIE UNIVERSITY   (Canada)

^b DALHOUSIE UNIVERSITY   (Canada)

^c QUEEN ELIZABETH II HEALTH SCIENCES CENTRE   (Canada)

^d INSTITUTE FOR RESEARCH IN IMMUNOLOGY AND CANCER   (Canada)

^e CHILDREN S HOSPITAL OF EASTERN ONTARIO   (Canada)

^f SCRIPPS RESEARCH INSTITUTE   (United States)

Author keywords

Brain; CD3+ cells; Demyelination; Lesions; Microglia

Indexed keywords

BETA1A INTERFERON; GLATIRAMER; INHIBITOR OF APOPTOSIS PROTEIN; INHIBITOR OF APOPTOSIS PROTEIN 1; INHIBITOR OF APOPTOSIS PROTEIN 2; INTERFERON BETA SERINE; MESSENGER RNA; NEURONAL APOPTOSIS INHIBITORY PROTEIN; SURVIVIN; X LINKED INHIBITOR OF APOPTOSIS;

ADULT; APOPTOSIS; ARTICLE; AUTOIMMUNITY; AUTOPSY; BLOOD SAMPLING; BRAIN TISSUE; CONTROLLED STUDY; DEMYELINATION; DISEASE COURSE; DISEASE DURATION; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOCOMPETENT CELL; IMMUNOMODULATION; MAJOR CLINICAL STUDY; MALE; MICROGLIA; MULTIPLE SCLEROSIS; NUCLEOTIDE SEQUENCE; PATHOGENESIS; PATHOPHYSIOLOGY; PERIPHERAL BLOOD MONONUCLEAR CELL; PROTEIN EXPRESSION; PROTEIN FAMILY; PROTEIN LOCALIZATION; RELAPSE; REMISSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; T LYMPHOCYTE;

ADULT; AGED; AUTOIMMUNITY; BLOTTING, WESTERN; BRAIN; DEMYELINATING DISEASES; FEMALE; GENE EXPRESSION; GENE EXPRESSION PROFILING; HUMANS; IMMUNOLOGIC FACTORS; INHIBITOR OF APOPTOSIS PROTEINS; MALE; MICROGLIA; MICROTUBULE-ASSOCIATED PROTEINS; MIDDLE AGED; MULTIPLE SCLEROSIS; NEOPLASM PROTEINS; NEURONAL APOPTOSIS-INHIBITORY PROTEIN; T-LYMPHOCYTES; X-LINKED INHIBITOR OF APOPTOSIS PROTEIN;

EID: 46849112798     PISSN: 13524585     EISSN: None     Source Type: Journal    
DOI: 10.1177/1352458507087468     Document Type: Article

References (78)

1. Noseworthy, JH, Lucchinetti, C, Rodriguez, M, Weinshenker, BG. Medical progress: multiple sclerosis. New Engl J Med 2000; 343: 938-952.
2. McDonnell, GV, Hawkins, SA. Primary progressive multiple sclerosis: increasing clarity but many unanswered questions. J Neurol Sci 2002; 199: 1-15.
3. Hawkins, SA, McDonnell, GV. Benign multiple sclerosis? Clinical course, long term follow up, and assessment of prognostic factors. J Neurol Neurosurg Psychiatry 1999; 67: 148-152.
4. Pittock, SJ, Mayr, WT, McClelland, RL, et al. Disability profile of MS did not change over 10 years in a population-based prevalence cohort. Neurology 2004; 62: 601-606.
5. Sayao, AL, Devonshire, V, Tremlett, H. Longitudinal follow-up of 'benign' multiple sclerosis at 20 years. Neurology 2007; 68: 496-500.
6. McDonnell, GV, Cabrera-Gomez, J, Calne, DB, Li, DKB, Oger, J. Clinical presentation of primary progressive multiple sclerosis 10 years after the incidental finding of typical magnetic resonance imaging brain lesions - the subclinical stage of primary progressive multiple sclerosis may last 10 years. Mult Scler 2003; 9: 204-209.
7. De Stefano, N, Battaglini, M, Stromillo, ML, et al. Brain damage as detected by magnetization transfer imaging is less pronounced in benign than in early relapsing multiple sclerosis. Brain 2006; 129: 2008-2016.
8. Rinaldi, L, Gallo, P, Calabrese, M, et al. Longitudinal analysis of immune cell phenotypes in early stage multiple sclerosis: distinctive patterns characterize MRI-active patients. Brain 2006; 129: 1993-2007.
9. Jensen, J, Langkilde, AR, Frederiksen, JL, Sellebjerg, F. CD8(+) T cell activation correlates with disease activity in clinically isolated syndromes and is regulated by interferon-beta treatment. J Neuroimmunol 2006; 179: 163-172.
10. Siva, A. The spectrum of multiple sclerosis and treatment decisions. Clin Neurol Neurosurg 2006; 108: 333-338.
11. Bernard, CCA, Derosbo, NK. Multiple-sclerosis - an autoimmune-disease of multifactorial etiology. Curr Opin Immunol 1992; 4: 760-765.
12. Pender, MP. Genetically determined failure of activation-induced apoptosis of autoreactive T cells as a cause of multiple sclerosis. Lancet 1998; 351: 978-981.
13. Pender, MP, Rist, MJ. Apoptosis of inflammatory cells in immune control of the nervous system: Role of glia. Glia 2001; 36: 137-144.
14. Dsouza, SD, Bonetti, B, Balasingam, V, et al. Multiple sclerosis: Fas signaling in oligodendrocyte cell death. J Exp Med 1996; 184: 2361-2370.
15. Satoh, J, Nakanishi, M, Koike, F, et al. Microarray analysis identifies an aberrant expression of apoptosis and DNA damage-regulatory genes in multiple sclerosis. Neurobiol Dis 2005; 18: 537-550.
16. Holcik, M, Gibson, H, Korneluk, RG. XIAP: apoptotic brake and promising therapeutic target. Apoptosis 2001; 6: 253-261.
17. Salvesen, GS, Duckett, CS. IAP proteins: blocking the road to death's door. Nature Rev Mol Cell Biol 2002; 3: 401-410.
18. Eckelman, BP, Salvesen, GS. The human anti-apoptotic proteins cIAP1 and cIAP2 bind but do not inhibit caspases. J Biol Chem 2006; 281: 3254-3260.
19. Nachmias, B, Ashhab, Y, Ben Yehuda, D. The inhibitor of apoptosis protein family (IAPs): an emerging therapeutic target in cancer. Semin Cancer Biol 2004; 14: 231-243.
20. Robertson, GS, Crocker, SJ, Nicholson, DW, Schulz, JB. Neuroprotection by the inhibition of apoptosis. Brain Pathol 2000; 10: 283-292.
21. Damiano, JS, Newman, RM, Reed, JC. Multiple roles of CLAN (caspase-associated recruitment domain, leucine-rich repeat, TPI-containing protein) in the and NAIP CIIA HET-E, and mammalian innate immune response. J Immunol 2004; 173: 6338-6345.
22. Segal, BM, Cross, AH. Fas(t) track to apoptosis in MS - TNF receptors may suppress or potentiate CNS demyelination. Neurology 2000; 55: 906-907.
23. Sharief, MK, Noori, MA, Zoukos, Y. Reduced expression of the inhibitor of apoptosis proteins in T cells from patients with multiple sclerosis following interferon-beta therapy. J Neuroimmunol 2002; 129: 224-231.
24. Sharief, MK, Semra, YK. Upregulation of the inhibitor of apoptosis proteins in activated T lymphocytes from patients with multiple sclerosis. J Neuroimmunol 2001; 119: 350-357.
25. McDonald, WI, Compston, A, Edan, G, et al. Recommended diagnostic criteria for multiple sclerosis: guidelines from the International Panel on the Diagnosis of Multiple Sclerosis. Ann Neurol 2001; 50: 121-127.
26. Polman, CH, Reingold, SC, Edan, G, et al. Diagnostic criteria for multiple sclerosis: 2005 Revisions to the 'McDonald Criteria'. Ann Neurol 2005; 58: 840-846.
27. Lublin, FD, Reingold, SC. Defining the clinical course of multiple sclerosis: results of an international survey. Neurology 1996; 46: 907-911.
28. Biswas, P, Mantelli, B, Sica, A, et al. Expression of CD4 on human peripheral blood neutrophils. Blood 2003; 101: 4452-4456.
29. Stroncek, DF, Clay, ME, Smith, J, Jaszcz, WB, Herr, G, McCullough, J. Comparison of two blood cell separators in collecting peripheral blood stem cell components. Transfus Med 1997; 7: 95-99.
30. Livak, KJ, Schmittgen, TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods 2001; 25: 402-408.
31. Feuer, R, Mena, I, Pagarigan, RR, Harkins, S, Hassett, DE, Whitton, JL. Coxsackievirus B3 and the neonatal CNS - The roles of stem cells, developing neurons, and apoptosis in infection, viral dissemination, and disease. Am J Pathol 2003; 163: 1379-1393.
32. Kutzelnigg, A, Lucchinetti, CF, Stadelmann, C, et al. Cortical demyelination and diffuse white matter injury in multiple sclerosis. Brain 2005; 128: 2705-2712.
33. Chofflon, M. Mechanisms of action for treatments in multiple sclerosis - does a heterogeneous disease demand a multi-targeted therapeutic approach? Biodrugs 2005; 19: 299-308.
34. Roy, N, Mahadevan, MS, McLean, M, et al. The gene for neuronal apoptosis inhibitory protein is partially deleted in individuals with spinal muscular-atrophy. Cell 1995; 80: 167-178.
35. Velasco, E, Valero, C, Valero, A, Moreno, F, Hernandez-Chico, C. Molecular analysis of the SMN and NAIP genes in Spanish spinal muscular atrophy (SMA) families and correlation between number of copies of (c)BCD541 and SNA phenotype (vol 5, pg 257, 1996). Hum Mol Genet 1996; 5: 710.
36. Martin, Y, Valero, A, Lopez-Terradas, JM, Marsal, C, Hernandez-Chico, C. The X-linked IAP gene does not contribute to the clinical phenotype of spinal muscular atrophy. Clin Genets 2000; 57: 154-156.
37. Crocker, SJ, Wigle, N, Liston, P, et al. NAIP protects the nigrostriatal dopamine pathway in an intrastriatal rat model of Parkinson's disease. Eur J Neurosci 2001; 14: 391-400.
38. Liston, P, Roy, N, Tamai, K, et al. Suppression of apoptosis in mammalian cells by NAIP and a related family of IAP genes. Nature 1996; 379: 349-353.
39. Pari, G, Berrada, F, Verge, G, Karpati, G, Nalbantoglu, J. Immunolocalization. of NAIP in the human brain and spinal cord. Neuroreport 2000; 11: 9-14.
40. Greer, JM, Csurhes, PA, Pender, MP, McCombe, PA. Effect of gender on T-cell proliferative responses to myelin proteolipid protein antigens in patients with multiple sclerosis and controls. J Autoimmun 2004; 22: 345-352.
41. Willard, HF, Riordan, JR. Assignment of the gene for myelin proteolipid protein to the X-chromosome - implications for X-linked myelin disorders. Science 1985; 230: 940-942.
42. Damiano, JS, Oliveira, V, Welsh, K, Reed, JC. Heterotypic interactions among NACHT domains: implications for regulation of innate immune responses. Biochem J 2004; 381: 213-219.
43. Killestein, J, Den Drijver, BF, Van der Graaff, WL, Uitdehaag, BMJ, Polman, CH, Van Lier, RAW. Intracellular cytokine profile in T-cell subsets of multiple sclerosis patients: different features in primary progressive disease. Mult Scler 2001; 7: 145-150.
44. Greer, JM, Csurhes, PA, Cameron, KD, McCombe, PA, Good, MF, Pender, MP. Increased immunoreactivity to two overlapping peptides of myelin proteolipid protein in multiple sclerosis. Brain 1997; 120: 1447-1460.
45. Acarin, N, Rio, J, Fernandez, AL, et al. Different antigan-glioside antibody pattern between relapsing-remitting and progressive multiple sclerosis. Acta Neurol Scand 1996; 93: 99-103.
46. Pender, MP, Csurhes, PA, Wolfe, NP, et al. Increased circulating T cell reactivity to GM3 and GQ1b gangliosides in primary progressive multiple sclerosis. J Clin Neurosci 2003; 10: 63-66.
47. Yuo, A, Kitagawa, S, Motoyoshi, K, Azuma, E, Saito, M, Takaku, F. Rapid priming of human monocytes by human hematopoietic growth-factors - granulocyte-macrophage colony-stimulating factor (Csf), macrophage-Csf, and interleukin-3 selectively enhance superoxide release triggered by receptor-mediated agonists. Blood 1992; 79: 1553-1557.
48. Zehntner, SP, Brickman, C, Bourbonniere, L, Remington, L, Caruso, M, Owens, T. Neutrophils that infiltrate the central nervous system regulate T cell responses. J Immunol 2005; 174: 5124-5131.
49. Todaro, M, Zeuner, A, Stassi, G. Role of apoptosis in autoimmunity. J Clin Immunol 2004; 24: 1-11.
50. O'Neill, AJ, Doyle, BT, Molloy, E, et al. Gene expression profile of inflammatory neutrophils: alterations in the inhibitors of apoptosis proteins during spontaneous and delayed apoptosis. Shock 2004; 21: 512-518.
51. Ishikawa, F, Miyazaki, S. New biodefense strategies by neutrophils. Arch Immunol Ther Exp (Warsz) 2005; 53: 226-233.
52. Diez, E, Yaraghi, Z, MacKenzie, A, Gros, P. The neuronal apoptosis inhibitory protein (Naip) is expressed in macrophages and is modulated after phagocytosis and during intracellular infection with Legionella pneumophila. J Immunol 2000; 164: 1470-1477.
53. Libbey, JE, McCoy, LL, Fujinami, RS. Molecular mimicry in multiple sclerosis. In: Alireza, M, (ed.) International Review of Neurobiology The Neurobiology of Multiple Sclerosis. New York: Academic Press, 2007: 127-147.
54. Tamm, I, Kornblau, SM, Segall, H, et al. Expression and prognostic significance of IAP-family genes in human cancers and myeloid leukemias. Clin Cancer Res 2000; 6: 1796-1803.
55. van der Goes, A, Boorsma, W, Hoekstra, K, Montagne, L, de Groot, CJA, Dijkstra, CD. Determination of the sequential degradation of myelin proteins by macrophages. J Neuroimmunol 2005; 161: 12-20.
56. Raivich, G, Banati, R. Brain microglia and blood-derived macrophages: molecular profiles and functional roles in multiple sclerosis and animal models of autoimmune demyelinating disease. Brain Res Rev 2004; 46: 261-281.
57. Djukic, M, Mildner, A, Schmidt, H, et al. Circulating monocytes engraft in the brain, differentiate into microglia and contribute to the pathology following meningitis in mice. Brain 2006; 129: 2394-2403.
58. Leone, C, Le Pavec, G, Meme, W, et al. Characterization of human monocyte-derived microglia-like cells. Glia 2006; 54: 183-192.
59. Bechmann, I, Goldmann, J, Kovac, AD, et al. Circulating monocytic cells infiltrate layers of anterograde axonal degeneration where they transform into microglia. FASEB J 2005; 19: 647.
60. Mezey, E, Chandross, KJ, Harta, G, Maki, RA, McKercher, SR. Turning blood into brain: cells bearing neuronal antigens generated in vivo from bone marrow. Science 2000; 290: 1779-1782.
61. Ponomarev, E, Shriver, L, Maresz, K, Dittel, B. Microglial cell activation and proliferation precedes the onset of CNS autoimmunity. J Neurosci Res 2005; 81: 389.
62. Miranda, MB, Dyer, KF, Grandis, JR, Johnson, DE. Differential activation of apoptosis regulatory pathways during monocytic vs granulocytic differentiation: a requirement for Bcl-X-L and XIAP in the prolonged survival of monocytic cells. Leukemia 2003; 17: 390-400.
63. Liston, P, Fong, WG, Komeluk, RG. The inhibitors of apoptosis: there is more to life than Bcl2. Oncogene 2003; 22: 8568-8580.
64. Vischioni, B, van der Valk, P, Ing, SWS, Kruyt, FAE, Rodriguez, JA, Giaccone, G. Expression and localization of inhibitor of apoptosis proteins in normal human tissues. Hum Pathol 2006; 37: 78-86.
65. Reed, JC, Doctor, K, Rojas, A, et al. Comparative analysis of apoptosis and inflammation genes of mice and humans. Genome Research 2003; 13: 1376-1388.
66. Skulina, C, Schmitt, S, Dornmair, K, Babbe, H, Roers, A, Rajewsky, K, et al. Multiple sclerosis: Brain-infiltrating CD8(+) T cells persist as clonal expansions in the cerebrospinal fluid and blood. PNAS 2004; 101: 2428-2433.
67. Barnett, MH, Henderson, APD, Prineas, JW. The macrophage in MS: just a scavenger after all? Pathology and pathogenesis of the acute MS lesion. Mult Scler 2006; 12: 121-132.
68. Lassmann, H, Bruck, W, Lucchinetti, CF. The immunopathology of multiple sclerosis: an overview. Brain Pathol 2007; 17: 210-218.
69. Nyland, H, Mork, S, Matre, R. Insitu characterization of mononuclear cell infiltrates in lesions of multiple-sclerosis. Neuropathol Appl Neurobiol 1982; 8: 403-411.
70. Khoury, SJ, Guttmann, CRG, Orav, EJ, Kikinis, R, Jolesz, FA, Weiner, HL. Changes in activated T cells in the blood correlate with disease activity in multiple sclerosis. Arch Neurol 2000; 57: 1183-1189.
71. Ambrosini, G, Adida, C, Altieri, DC. A novel antiapoptosis gene, survivin, expressed in cancer and lymphoma. Nature Med 1997; 3: 917-921.
72. Fukuda, S, Pelus, LM. Regulation of the inhibitor-of-apoptosis family member survivin in normal cord blood and bone marrow CD34(+) cells by hematopoietic growth factors: implication of survivin expression in normal hematopoiesis. Blood 2001; 98: 2091-2100.
73. Ouhtit, A. Survivin is not only a death encounter but also a survival protein for invading tumor cells. Front Biosci 2007; 1: 1260-1270.
74. Kornacker, M, Verneris, MR, Kornacker, B, Scheffold, C, Negrin, RS. Survivin expression correlates with apoptosis resistance after lymphocyte activation and is found preferentially in memory T cells. Immunol Lett 2001; 76: 169-173.
75. Maurer, M, Loserth, S, Kolb-Maurer, A, et al. A polymorphism in the human cytotoxic T-lymphocyte antigen 4 (CTLA4) gene (exon 1+49) alters T-cell activation. Immunogenetics 2002; 54: 1-8.
76. de Graaf, AO, van Krieken, JH, Tonnissen, E, et al. Expression of C-IAP1, C-IAP2 and SURVIVIN discriminates different types of lymphoid malignancies. Br J Haematol 2005; 130: 852-859.
77. Zehntner, SP, Bourbonniere, L, Moore, CS, et al. X-linked inhibitor of apoptosis (XIAP) regulates T cell effector function. J Immunol 2007; 179: 7553-7560.
78. Zehntner, SP, Bourbonniere, L, Morris, SJ, et al. Apoptosis induction as a therapeutic intervention to eliminate encephallitogenic T cells; Antisense XIAP (AEG35169) in murine models of EAE. Clin Immunol 2005; 115: S36-S37.